Here are four observations:
1. Ten research firms in total have issued ratings on NuVasive within the last year.
2. The highest estimate of the 10 analysts is that stock will reach $63 within the next year, while the lowest estimate sets the target price at $49.
3. Analysts have also placed the consensus earnings per share estimate for the current year at $1.13.
4. NuVasive recently reported financial results for the first quarter of 2015. NuVasive increased revenue 8.4 percent to $192.4 million in the first quarter. Also, full year 2015 GAAP earnings per share were projected at $1.12, compared to GAAP loss per share of $0.36 for 2014.
More articles on devices:
5 key trends in the U.S. orthopedic stem cell market
5 key trends in the North America internal trauma fixation device market
From the garage to a global company: 7 key notes from K2M CEO Eric Major
